Hikal Share Price
Hikal Share Price Today
As of 5 Jul 2026, Hikal share price is ₹222.10. The stock opened at ₹224.85, compared to its previous close of ₹223.09. During today's trading session, Hikal share price moved in the range of ₹220.32 to ₹225.75, with an average price of ₹223.03 for the day. Looking at its last 52-week, the stock has touched a low of ₹146.25 and a high of ₹355.00. On the performance front, Hikal share price has declined by 2.14% over the last six months and is down 36.05% on a year-on-year basis.
Hikal Returns Calculator
Hikal Shareholder Returns
Hikal Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Hikal Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,859.80 | ₹1,784.60 | ₹2,023.03 | ₹1,942.72 |
| Other Income | ₹5.00 | ₹2.50 | ₹5.41 | ₹4.89 |
| Total Revenue | ₹1,864.80 | ₹1,787.10 | ₹2,028.44 | ₹1,947.61 |
| Total Expenses | ₹1,741.00 | ₹1,691.60 | ₹1,923.08 | ₹1,729.05 |
| Profit Before Tax | ₹123.80 | ₹95.50 | ₹105.37 | ₹218.56 |
| Tax | ₹33.00 | ₹25.90 | ₹26.98 | ₹58.06 |
| Profit After Tax | ₹90.80 | ₹69.60 | ₹78.38 | ₹160.50 |
| EPS - Basic | ₹7.36 | ₹5.64 | ₹6.36 | ₹13.02 |
| EPS - Diluted | ₹7.36 | ₹5.64 | ₹6.36 | ₹13.02 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹123.80 | ₹95.51 | ₹105.37 | ₹218.56 |
| Income before WC changes | ₹338.90 | ₹270.38 | ₹268.50 | ₹344.83 |
| Change in Assets | -₹43.90 | -₹41.52 | ₹22.44 | -₹72.98 |
| Change in Liabilities | ₹15.20 | -₹11.80 | ₹53.17 | ₹91.68 |
| Change in WC | -₹28.70 | -₹53.32 | ₹75.61 | ₹18.70 |
| Cash flow from Operations | ₹280.40 | ₹186.72 | ₹315.31 | ₹293.73 |
| Cash flow from Investing | -₹136.50 | -₹173.75 | -₹292.34 | -₹284.37 |
| Cash flow from Financing | -₹143.60 | -₹27.00 | -₹7.68 | -₹5.56 |
| Total Cash Flow | ₹0.30 | -₹14.03 | ₹15.29 | ₹3.80 |
| Cash (Start of the year) | ₹12.70 | ₹26.73 | ₹11.44 | ₹7.64 |
| Cash (End of the year) | ₹13.00 | ₹12.70 | ₹26.73 | ₹11.44 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,533.50 | ₹1,520.50 | ₹1,446.46 | ₹1,248.83 |
| Current Assets | ₹995.40 | ₹966.60 | ₹939.02 | ₹964.28 |
| Total Assets | ₹2,528.90 | ₹2,487.10 | ₹2,385.48 | ₹2,213.11 |
| Current Liabilities | ₹789.50 | ₹756.60 | ₹661.55 | ₹769.18 |
| Net Current Asset | ₹205.90 | ₹210.00 | ₹277.47 | ₹195.10 |
| Non-Current Liabilities | ₹477.10 | ₹542.80 | ₹590.46 | ₹375.94 |
| Equity Capital | ₹1,262.30 | ₹1,187.70 | ₹1,133.47 | ₹1,067.98 |
| Total Equity & Liabilities | ₹2,528.90 | ₹2,487.10 | ₹2,385.48 | ₹2,213.11 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,859.80 | ₹1,784.60 | ₹2,023.03 | ₹1,942.72 |
| Other Income | ₹5.00 | ₹2.50 | ₹5.41 | ₹4.89 |
| Total Revenue | ₹1,864.80 | ₹1,787.10 | ₹2,028.44 | ₹1,947.61 |
| Total Expenses | ₹1,740.90 | ₹1,691.70 | ₹1,923.08 | ₹1,729.04 |
| Profit Before Tax | ₹123.90 | ₹95.40 | ₹105.36 | ₹218.57 |
| Tax | ₹33.00 | ₹25.90 | ₹26.98 | ₹58.06 |
| Profit After Tax | ₹90.90 | ₹69.50 | ₹78.38 | ₹160.51 |
| EPS - Basic | ₹7.37 | ₹5.64 | ₹6.36 | ₹13.02 |
| EPS - Diluted | ₹7.37 | ₹5.64 | ₹6.36 | ₹13.02 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹123.90 | ₹95.40 | ₹105.36 | ₹218.57 |
| Income before WC changes | ₹339.00 | ₹270.30 | ₹268.49 | ₹344.84 |
| Change in Assets | -₹44.10 | -₹41.50 | ₹22.44 | -₹72.98 |
| Change in Liabilities | ₹15.30 | -₹11.90 | ₹53.17 | ₹91.67 |
| Change in WC | -₹28.80 | -₹53.40 | ₹75.60 | ₹18.69 |
| Cash flow from Operations | ₹280.40 | ₹186.60 | ₹315.29 | ₹293.73 |
| Cash flow from Investing | -₹136.50 | -₹173.70 | -₹292.34 | -₹284.37 |
| Cash flow from Financing | -₹143.60 | -₹27.00 | -₹7.68 | -₹5.56 |
| Total Cash Flow | ₹0.30 | -₹14.10 | ₹15.27 | ₹3.80 |
| Cash (Start of the year) | ₹12.60 | ₹26.70 | ₹11.44 | ₹7.64 |
| Cash (End of the year) | ₹12.90 | ₹12.60 | ₹26.71 | ₹11.44 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,532.20 | ₹1,520.50 | ₹1,446.47 | ₹1,248.84 |
| Current Assets | ₹996.90 | ₹966.50 | ₹939.01 | ₹964.28 |
| Total Assets | ₹2,529.10 | ₹2,487.00 | ₹2,385.48 | ₹2,213.12 |
| Current Liabilities | ₹789.80 | ₹756.60 | ₹661.53 | ₹769.17 |
| Net Current Asset | ₹207.10 | ₹209.90 | ₹277.48 | ₹195.11 |
| Non-Current Liabilities | ₹477.10 | ₹542.80 | ₹590.46 | ₹375.94 |
| Equity Capital | ₹1,262.20 | ₹1,187.60 | ₹1,133.49 | ₹1,068.01 |
| Total Equity & Liabilities | ₹2,529.10 | ₹2,487.00 | ₹2,385.48 | ₹2,213.12 |
About Hikal
Hikal Limited is a Mumbai-based chemicals company. It specialises in research, development and manufacturing of fine chemicals, agrochemicals and pharmaceutical intermediates.
In 1988, the company started manufacturing and selling chemicals, intermediates, medicines and insecticides. Hikal Chemical Industries Limited (HCIL) was a joint venture between the Hiremath family and Surajmukhi Investment and Finance Limited, a fully-owned subsidiary of Kalyani Steels Limited.
Hikal Limited became a full-fledged public limited company in 1994. The year 2000 saw the rebranding of Hikal Chemical Industries Ltd to Hikal Ltd. The company's plan to diversify into agrochemicals, pharmaceuticals and biotech is reflected in the name change. In 2005, Hikal Ltd and Crompton Corporation USA signed a long-term agreement to produce and supply a next-generation crop protection product.
In 2008, the company founded Acoris Research Ltd., a fully operational contract research facility situated at the International Biotech Park Pune. A year later in 2009, the company enhanced its manufacturing capabilities. The construction of a new multi-purpose plant for active ingredients in crop protection at the Taloja site, in Maharashtra, was successfully concluded. It commissioned several new multipurpose Active Pharmaceutical Ingredient (API) plants in Bangalore, which holds approval from the US Food and Drug Administration (FDA). A new multipurpose pharmaceutical intermediates plant was established in Panoli, Gujarat.
The market capitalisation of Hikal Limited is over ₹3,700 crore as of January 11, 2024. Hikal share price has gained over 70% in the last three years.
Business operations
Hikal’s business is divided into two segments – crop protection and pharmaceuticals, with a broad portfolio of goods and services to meet the client's changing demands. In its crop protection segment, the company combines research and technology, production skills and intellectual capital to deliver top-notch crop protection products, including insecticides, fungicides, herbicides, biocides and intermediates.
Hikal Limited provides active pharmaceutical ingredients, active ingredients and intermediates to international clients. Its facilities are also designed to cater to the customised requirements of clients in the United States, Europe and Japan. There was a substantial increase in its global customers in 2023 after the introduction of new products within the antidiabetic therapeutic category.
The crop protection division experienced a 12% annual revenue growth, reaching a total revenue of ₹907.9 crore in FY23. The pharmaceutical division reported revenues amounting to ₹1,115 crore during the same period.
The company operates five manufacturing facilities across India situated in Taloja and Mahad in Maharashtra, Panoli in Gujarat and Jigani in Karnataka. It also runs a research & technology centre in Maharashtra’s Pune. These facilities undergo regular inspections by multinational corporations and global regulatory authorities. Hikal's R&D has a comprehensive infrastructure that includes 11 synthetic laboratories, four analytical labs and one process intensification lab.
Hikal Financial Highlights
- Revenue: Hikal reported revenue of ₹1,724.90 crore in FY26 vs ₹1,864.80 crore in FY25. It showed a decrease of 7.50% on a yearly basis.
- Operating Profit: Hikal reported an operating loss of ₹78.30 crore in FY26 vs ₹123.80 crore in FY25. It showed a decrease of 163.25% on a year-on-year basis.
- Net Profit: Hikal reported a net loss of ₹48.80 crore in FY26 vs ₹90.80 crore in FY25. It showed a decrease of 153.74% on a yearly basis.
Hikal Quarterly Result Highlights
- Hikal reported revenue of ₹526.00 crore in Mar 2026, compared with ₹497.10 crore in Dec 2025, representing an increase of 5.81% on a quarter-on-quarter (QoQ) basis.
- Hikal reported an operating profit of ₹8.30 crore in Mar 2026, compared with ₹9.20 crore in Dec 2025, representing an increase of 190.22% on a quarter-on-quarter (QoQ) basis.
- Hikal reported a profit of ₹14.40 crore in Mar 2026, compared with ₹5.90 crore in Dec 2025, reflecting an increase of 344.07% on a QoQ basis.
- The earnings per share (EPS) of Hikal stood at ₹7.36 during Mar 2026.
Similar Stocks
FAQs on Hikal Share Price
What is Hikal share price today?
Hikal share price is ₹222.10 as on 03 Jul, 2026, 15:56 IST.
How has the Hikal share price performed in the past?
In the last 1 year, Hikal delivered a return of -36.05%. The Hikal share price hit a high of ₹355.00 and low of ₹146.25.
How much is the Mutual Fund shareholding in Hikal shares?
The Mutual Fund Shareholding in Hikal was 5.92% at the end of Mar 2026.
What is the the 52-week high and low of Hikal shares ?
The 52-week high and low of Hikal share is ₹355.00 and ₹146.25 as of 03 Jul, 2026.
What is the market cap of Hikal?
The market capitalisation of Hikal is ₹2,751.46 Crores as on 03 Jul, 2026.
What are the stock symbols of Hikal?
The stock symbol of Hikal is HIKAL on the NSE, 524735 on the BSE, and the ISIN is INE475B01022.
What was yesterday's closing price of Hikal shares ?
Hikal shares closed yesterday at ₹223.09 on NSE & ₹223.15 on BSE
How to buy Hikal shares?
To buy Hikal shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Hikal shares on Holidays?
No, shares of Hikal or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Hikal shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Hikal?
The PE and PB ratio of Hikal is -56.35 and 2.3 respectively, as on 03 Jul, 2026, 15:56 IST.